PIII vs MOH vs CNC vs ALHC

For growth investors, Alignment Healthcare, Inc.

(ALHC) is the stronger pick with 46. 1% revenue growth year-over-year, versus 11. 7% for Molina Healthcare, Inc. (MOH). Molina Healthcare, Inc. (MOH) offers the better valuation at 21. 5x trailing P/E (36. 1x forward), making it the more compelling value choice. Analysts rate P3 Health Partners Inc. (PIII) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Centene Corporation is actually cheaper at 16.

4x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Centene Corporation (CNC) delivered a total return of -22.

0%, compared to -99. 3% for P3 Health Partners Inc. (PIII). Over 10 years, the gap is even starker: MOH returned +294. 2% versus PIII's -99. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Molina Healthcare, Inc.

(MOH) is the lower-risk stock at -0. 06β versus Alignment Healthcare, Inc. 's 0. 81β — meaning ALHC is approximately -1541% more volatile than MOH relative to the S&P 500. On balance sheet safety, Centene Corporation (CNC) carries a lower debt/equity ratio of 94% versus 189% for Alignment Healthcare, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Alignment Healthcare, Inc.

(ALHC) is pulling ahead at 46. 1% versus 11. 7% for Molina Healthcare, Inc. (MOH). On earnings-per-share growth, the picture is similar: Alignment Healthcare, Inc. grew EPS 99. 4% year-over-year, compared to -315. 8% for Centene Corporation. Over a 3-year CAGR, ALHC leads at 40. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Molina Healthcare, Inc.

(MOH) is the more profitable company, earning 1. 0% net margin versus -9. 1% for P3 Health Partners Inc. — meaning it keeps 1. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MOH leads at 1. 7% versus -21. 4% for PIII. At the gross margin level — before operating expenses — PIII leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Centene Corporation (CNC) trades at 16.

4x forward P/E versus 101. 8x for Alignment Healthcare, Inc. — 85. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PIII: 249. 2% to $12. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Molina Healthcare, Inc.

(MOH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 06), +294. 2% 10Y return). Both have compounded well over 10 years (MOH: +294. 2%, ALHC: +3. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: PIII is a small-cap high-growth stock; MOH is a small-cap quality compounder stock; CNC is a mid-cap high-growth stock; ALHC is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.